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Background/Aims
Although prolonged post-operative ileus (PPOI) is an important factor for the prolonged length of post-operative hospital stay, there 
is still a lack of effective predictive and therapeutic methods for PPOI. Previous studies reported that increased inflammatory markers, 
such as C-reactive protein (CRP) level and neutrophil to lymphocyte ratio (NLR), are associated with malignancies. The aim of our study 
is to elucidate the association between peri-operative inflammatory markers and PPOI after gastrectomy for gastric cancer.
Methods
We enrolled patients who received gastrectomy for gastric cancer from June 2013 to January 2016 at a single tertiary referral center 
in Seoul, Korea. We evaluated peri-operative inflammatory markers, including CRP level, NLR, and platelet to lymphocyte ratio (PLR) of 
enrolled patients. We compared these data between control group and PPOI group.
Results
A total of 390 subjects were enrolled in this study, and 132 patients (33.8%) showed PPOI. In univariate analysis, preoperative CRP 
level and NLR, post-operative day (POD) 1 CRP level, NLR, and PLR, and POD3 CRP level, NLR, and PLR were significantly associated 
with PPOI. In multivariate analysis, preoperative NLR (P = 0.014), POD1 NLR (P = 0.019), POD3 CRP (P = 0.004), and POD3 NLR (P = 
0.008) were independent risk factors for PPOI.
Conclusions
Peri-operative inflammatory markers, such as CRP level and NLR, are useful predictive factors for PPOI who received gastrectomy for 
gastric cancer. Moreover, prophylactic antibiotics and anti-inflammatory drugs can be preventive and therapeutic agents for PPOI.
(J Neurogastroenterol Motil 2021;27:588-595)
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Introduction  
Post-operative ileus (POI) is known as a temporary impair-
ment of gastrointestinal (GI) motility after surgery.1 Patients who 
have POI present nausea, vomiting, and abdominal discomfort. 
Symptoms of POI also include a delayed passage of gas and stool 
or inability to tolerate oral diet.2 “Uncomplicated” or “normal” POI 
is typically identified as an unavoidable process following surgery, 
which generally resolves within 3 days.1,2 “Prolonged” or “paralytic” 
post-operative ileus (PPOI) extends beyond the duration of 3 
days.1,2 Internationally, there has been a lack of standardized defini-
tions for PPOI, but we believe post-operative day (POD) 4 to be 
the most acceptable cutoff point as proposed by Vather et al2 based 
on a systemic review and global study. Additionally, PPOI is an 
important factor for the prolongation of post-operative hospital stay 
and excessive hospitalization costs.3 
Globally, gastric cancer is the third common cause of cancer-
related mortality, and is the most prevalent type of cancer in Eastern 
Asia, including Japan, Korea, and China.4 Enhanced Recovery 
after Surgery (ERAS) programs were started to improve the post-
operative recovery process.5 As PPOI is one of the major factors 
that delays post-operative recovery,3,6 preventing POI is a key factor 
of ERAS.5 However, there is still a lack of effective therapeutic and 
predictive methods for POI. Gastrectomy is inevitably followed 
by physiologic inflammatory stimuli for surgical stress, which can 
be observed by elevated white blood cell and C-reactive protein 
(CRP) levels.7 However, cancer patients already have higher levels 
of preoperative CRP when compared to healthy people or patients 
with benign disease.8 Tumor growth may induce a peritumoral 
inflammatory growth and therefore, lead to an increase in CRP 
levels.7,9 It has been well known that chronic diseases such as gastric 
malignancy are associated with a prolonged inflammation which 
can be confirmed by the increase of other inflammatory param-
eters.10 Some hematological markers, such as neutrophil count, have 
been identified as both diagnostic and prognostic factors in various 
malignancies.11 The neutrophil to lymphocyte ratio (NLR) has 
been studied as a simple marker of systemic inflammatory reactions 
in not only patients with tumors,12,13 but also in patients following 
resection of a range of neoplasms,14 including gastric malignancy.15 
Further, the preoperative platelet to lymphocyte ratio (PLR) has 
also been proposed as an independent prognostic marker in pancre-
atic cancer.16 
Nonetheless, the association between peri-operative inflam-
matory markers and post-operative complications such as PPOI 
remains uncertain in gastric cancer surgery. The aim of our study 
is to investigate the relationship between PPOI and peri-operative 
inflammatory markers and to explore whether peri-operative NLR, 
PLR, or CRP levels could be useful independent prognostic indi-
cators for PPOI after gastric cancer surgery.
Materials and Methods 
Patients
A total of 435 patients who received gastrectomy for gastric 
cancer from June 2013 to January 2016, at a single tertiary referral 
center in Seoul, Korea were enrolled. The data from medical re-
cords were analyzed retrospectively. All subjects had a preoperative 
diagnosis of gastric adenocarcinoma on the basis of abdominal CT, 
esophagogastroduodenoscopy (EGD), and histology of biopsied 
specimens. The exclusion criteria were as follows: (1) patients who 
had gastric cancer in the remnant stomach (n = 10); (2) patients 
who underwent other combined intra-abdominal cancer surgery 
(n = 6); (3) unavailability of complete follow-up data (n = 29); 
and (4) patients who had infection which can affect on the inflam-
matory markers (n = 34)––surgical wound infection (n = 20), 
pneumonia (n = 9), colitis (n = 3), and acute pyelonephritis (n = 
2). Based on the above criteria, 390 patients were finally included 
for analysis. PPOI was defined as ileus persisting for more than 3 
days after surgery, and POI less than 3 days was categorized as un-
complicated POI. Enrolled patients were classified into 2 groups, 
the PPOI group and control (uncomplicated POI) group accord-
ing to the duration of POI. 
The study protocol conformed to the ethical guidelines of the 
World Medical Association Declaration of Helsinki and was ap-
proved by the Institutional Review Board of Gangnam Severance 
Hospital (IRB No. 3-2019-0265). Informed consent was not 
required as this study was a retrospective analysis of existing admin-
istrative and clinical data.
Data Collection
The preoperative demographic, clinical, and laboratory blood 
test data were obtained, including sex, age, body mass index (BMI), 
comorbidities including diabetes mellitus, objective of surgery 
(curative or palliative), previous chemotherapy and operation his-
tory, preoperative CRP level, neutrophil, lymphocyte, and platelet 
counts. Surgical factors including the type of surgery (open/con-
verted or laparoscopic operation, total or subtotal gastrectomy, com-
bined or not combined with multiorgan resection); type of recon-
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struction (Billroth I, Billroth II, or Roux-en-Y); and gastric outlet 
obstruction (partial or complete) were also retrieved. Post-operative 
outcomes included the day of flatulence. Post-operative laboratory 
blood test data were collected at POD1 and POD3, because leu-
kocytes increased during POD1 and CRP level peaked at POD3.7 
Resected specimens were examined histopathologically and staged 
according to the 8th edition of the American Joint Committee on 
Cancer tumor-node-metastasis (TNM) staging system.
Statistical Methods
We determined the optimal discriminator value for NLR, 
PLR, and CRP levels using receiver operating characteristic (ROC) 
curve analysis. At each value, the sensitivity and specificity for each 
outcome were plotted, generating a ROC curve. The ratio closest 
to the point with maximum sensitivity and specificity was selected 
as the cutoff value and comparisons between groups of patients 
were performed using the chi-squared test, where appropriate. A 
t test was used for distributed continuous data. Spearman’s rank 
correlation was used to assess the correlation between ranked data 
and other factors. To examine the effect of variables on the develop-
ment of PPOI, we used univariate and multivariate logistic regres-
sion analyses. Statistical significance was defined as P < 0.05. All 
analyses were conducted using the software program, SPSS ver22.0 
(IBM Corp, Armonk, NY, USA).
Results 
Among the 390 subjects who were analyzed, 132 patients who 
showed a POI for longer than 3 days were categorized as the PPOI 
group, and the other 258 subjects comprised the control group. 
Table 1 shows demographic and clinical characteristics of sub-
jects. The mean age of all the patients was 59.8 years. 311 patients 
(79.7%) received laparoscopic gastrectomy, and 78 patients (20.0%) 
received open gastrectomy. For 1 patient, the planned laparoscopic 
gastrectomy was converted to open gastrectomy in the operating 
room. Regarding the type of gastrectomy, 191 (49.0%) and 199 
(51.0%) patients received total and partial gastrectomy, respectively. 
In 25 patients, partial or complete gastric outlet obstruction were 
detected during operation. The Billroth I operation (gastroduodenal 
anastomosis), Billroth II operation (gastrojejunal anastomosis), and 
Roux-en-Y gastrojejunostomy were performed in 135 (34.6%), 43 
(11.0%), and 211 (54.1%) patients respectively. 
The association between clinicopathological characteristics and 
PPOI was analyzed. Table 2 presents the results of the univariate 
analysis. PPOI was associated with age ≥ 60 years (P = 0.019), 
male (P = 0.010), advanced TNM stage (III and IV, P = 0.004), 
absence of gastric outlet obstruction (P = 0.016), open/converted 
operative technique (P < 0.001), and a combination with other or-
Table 1. Demographic and Clinical Characteristics of Subjects
Characteristics of patients Overall (N = 390)
Age (yr) 59.8 ± 12.6
Sex
   Male 259 (66.4)
   Female 131 (33.6)
BMI (kg/m2) 23.7 ± 3.4
Past history (diabetes)
   No 338 (86.7)
   Yes 52 (13.3)
Objective of surgery
   Curative 379 (97.2)
   Palliative 11 (2.8)
TNM stage, AJCC 8th edition
   I 250 (64.1)
   II 55 (14.1)
   III 64 (16.4)
   IV 21 (5.4)
Gastric outlet obstruction
   No 365 (93.6)
   Partial 22 (5.6)
   Complete 3 (0.8)
Surgical approach
   Laparoscopic 311 (79.7)
   Open 78 (20.0)
   Open conversion 1 (0.3)
Type of gastrectomy
   Total 191 (49.0)
   Partial 199 (51.0)
Operation reconstruction
   Billroth I 135 (34.6)
   Billroth II 43 (11.0)
   Roux-en-Y 211 (54.1)
   Double tract 1 (0.3)
Adjacent organ resection
   No 324 (83.1)
   Colon 14 (3.6)
   Other 52 (13.3)
Previous chemotherapy
   No 354 (98.5)
   Yes 6 (1.5)
Previous operation
   No 356 (91.3)
   Yes 34 (8.7)
BMI, body mass index; TNM, tumor-node-metastasis; AJCC, American 
Joint Committee on Cancer.
Data are presented as mean ± SD or n (%).
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gan resection (P = 0.047). The other factors were not significantly 
associated with PPOI, including BMI, past history of diabetes, ob-
jective of surgery, types of reconstruction, previous chemotherapy, 
and previous operation history.
Peri-operative laboratory values were compared between the 
PPOI and control groups. Comparison of peri-operative laboratory 
Table 2. Relationship Between Clinicopathological Characteristics and Prolonged Post-operative Ileus in Patients Undergoing Gastrectomy: Uni-
variate Analysis
Variables Control (n = 258) PPOI (n = 132) P-value
Age (yr)
   < 60 134 (51.9) 52 (39.4) 0.019
   ≥ 60 124 (48.1) 80 (60.6)
Sex 
   Male 160 (62.0) 99 (75.0) 0.010
   Female 98 (38.0) 33 (25.0)
BMI (kg/m2)
   < 25 170 (65.9) 74 (56.1) 0.651
   ≥ 25 88 (34.1) 58 (43.9)
Past history (diabetes)
   No 229 (88.8) 109 (82.6) 0.089
   Yes 29 (11.2) 23 (17.4)
Objective of surgery
   Curative 252 (97.7) 127 (96.2) 0.409
   Palliative 6 (2.3) 5 (3.8)
TNM stage, AJCC 8th edition 
   I/II 213 (82.6) 92 (69.7) 0.004
   III/IV 45 (17.4) 40 (30.3)
Gastric outlet obstruction
   No 248 (96.1) 117 (88.6) 0.016
   Partial 9 (3.5) 13 (9.8)
   Complete 1 (0.4) 2 (1.5)
Surgical approach
   Laparoscopic 220 (85.3) 91 (68.9) < 0.001
   Open 37 (14.3) 41 (31.1)
   Open conversion 1 (0.4) 0 (0.0)
Operation reconstruction
   Billroth I 100 (38.8) 35 (26.5) 0.091
   Billroth II 26 (10.1) 17 (12.9)
   Roux-en-Y 131 (50.8) 80 (60.6)
   Double tract 1 (0.4) 0 (0.0)
Combined organ resection 
   No 217 (84.1) 107 (81.1) 0.047
   Colon 5 (1.9) 9 (6.8)
   Others 36 (14.0) 16 (12.1)
Previous chemotherapy
   No 256 (99.2) 128 (97.0) 0.087
   Yes 2 (0.8) 4 (3.0)
Previous operation
   No 237 (91.9) 119 (90.2) 0.571
   Yes 21 (8.1) 13 (9.8)
BMI, body mass index; TNM, tumor-node-metastasis; AJCC, American Joint Committee on Cancer.
Data are presented as n (%).
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data, including CRP level, NLR, and PLR, between the PPOI 
and control groups is summarized in Table 3. Peri-operative inflam-
matory markers showing significant differences were CRP level and 
NLR during preoperative period; NLR at POD1; and CRP level, 
NLR, and PLR at POD3, all of which were significantly higher in 
the PPOI group in contrast to the control group. However, there 
were no statistically significant differences in the preoperative PLR, 
POD1 CRP level, and POD1 PLR. 
We performed ROC curve analysis for pre and post-operative 
laboratory blood test data. For all 390 gastric cancer patients, the 
value with the highest sensitivity and specificity was selected. The 
preoperative CRP level, NLR, and PLR were 1.35 mg/L, 2.18, 
and 167.12, respectively. The POD1 CRP level, NLR, and PLR 
were 51.5 mg/L, 7.72, and 234.03, respectively. The POD3 CRP 
level, NLR, and PLR were 107.15 mg/L, 5.51, and 167.49, re-
spectively. The cutoff values of each inflammatory marker with their 
corresponding sensitivity and specificity are shown in Supplemen-
tary Table 1.
In univariate analysis, age ≥ 60 years, male sex, gastric out-
let obstruction, adjacent colon resection, open surgery, advanced 
TNM stage (III and IV), preoperative CRP level ≥ 1.35 mg/
L, preoperative NLR ≥ 2.18, POD1 CRP level ≥ 51.5 mg/
L, POD1 NLR ≥ 7.72, POD1 PLR ≥ 234.03, POD3 CRP 
level ≥ 107.15 mg/L, POD3 NLR ≥ 5.51, and POD3 PLR ≥ 
167.47 had significant association with PPOI (Table 4). The mul-
tivariate logistic regression analysis, conducted using the clinico-
Table 4. Clinicopathologic Characteristics and Prolonged Post-operative Ileus in Patients Undergoing Gastrectomy: Univariate and Multivariate 
Logistic Regression Analysis
Variables
Univariate analysis Multivariate analysis
χ2 P-value OR (95% Cl) P-value
Age ≥ 60 yr 5.508 0.019 1.527 (0.970-2.405) 0.067
Male 6.600 0.010 0.635 (0.388-1.039) 0.071
Gastric outlet obstruction 8.228 0.016 1.598 (0.130-19.655) 0.405
Adjacent colon resection 6.111 0.047 1.679 (0.480-5.878) 0.490
Open surgery 15.638 < 0.001 2.664 (1.561-4.547) 0.002
TNM stage (III/IV), AJCC 8th edition 8.474 0.004 1.225 (0.673-2.229) 0.506
Preoperative marker
   CRP ≥ 1.35 (mg/L) 4.169 0.041 1.307 (0.823-2.075) 0.256
   NLR ≥ 2.18 7.224 0.007 1.607 (1.006-2.565) 0.047
   PLR ≥ 167.12 3.569 0.059 1.464 (0.865-2.479) 0.156
POD1 marker
   CRP ≥ 51.5 (mg/L) 4.545 0.033 1.357 (0.857-2.148) 0.193
   NLR ≥ 7.72 7.643 0.006 1.778 (1.101-2.871) 0.019
   PLR ≥ 234.03 5.667 0.017 1.634 (0.921-2.899) 0.093
POD3 marker
   CRP ≥ 107.15 (mg/L) 15.933 < 0.001 1.987 (1.239-3.188) 0.004
   NLR ≥ 5.51 15.405 < 0.001 1.879 (1.177-2.998) 0.008
   PLR ≥ 167.49 6.079 0.014 1.552 (0.988-2.437) 0.057
PPOI, prolonged post-operative ileus; TNM, tumor-node-metastasis; AJCC, American Joint Committee on Cancer; CRP, C-reactive protein; NLR, neutrophil to 
lymphocyte ratio; PLR, platelet to lymphocyte ratio; POD, post-operative day. 








   CRP (mg/L) 2.55 ± 0.39 5.25 ± 13.76 0.034
   NLR 2.02 ± 1.19 2.28 ± 1.27 0.041
   PLR 134.34 ± 56.14 146.00 ± 73.49 0.087
POD1 marker
   CRP (mg/L) 46.19 ± 27.50 51.31 ± 28.09 0.085
   NLR 6.74 ± 4.01 7.79 ± 4.79 0.023
   PLR 172.59 ± 96.68 194.37 ± 128.82 0.063
POD3 marker
   CRP (mg/L) 103.31 ± 58.77 137.32 ± 69.84 < 0.001
   NLR 5.33 ± 3.02 6.76 ± 3.81 0.040
   PLR 172.42 ± 81.81 191.97 ± 100.97 < 0.001
PPOI, prolonged post-operative ileus; CRP, C-reactive protein; NLR, neu-
trophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; POD, post-
operative day.
Data are presented as mean ± SD.
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laboratory factors determined in the univariate analysis, identified 
that open surgery (OR, 2.664; 95% CI, 1.561-4.547; P = 0.002), 
preoperative NLR ≥ 2.18 (OR, 1.607; 95% CI, 1.006-2.565; P 
= 0.047), POD1 NLR ≥ 7.72 (OR, 1.778; 95% CI, 1.101-2.871; 
P = 0.019), POD3 CRP ≥ 107.15 mg/L (OR, 1.987; 95% CI, 
1.239-3.188; P = 0.004), and POD3 NLR ≥ 5.51 (OR, 1.879; 
95% CI, 1.177-2.998; P = 0.008) were independent risk factors 
for PPOI in patients with gastric cancer. 
We performed additional analysis in patients undergoing open 
gastrectomy and laparoscopic gastrectomy, respectively. In the uni-
variate analysis for open gastrectomy, preoperative NLR ≥ 2.18, 
POD1 NLR ≥ 7.72, and POD3 NLR ≥ 5.51 had significant as-
sociation with PPOI (Supplementary Table 2). In the multivariate 
analysis, preoperative NLR ≥ 2.18 (OR, 3.741; 95% CI, 1.327-
10.547; P = 0.013), POD1 NLR ≥ 7.72 (OR, 4.069; 95% CI, 
1.452-11.401; P = 0.008) were independent risk factors for PPOI 
in patients who underwent open surgery. 
In laparoscopic gastrectomy, age ≥ 60 years, male sex, gastric 
outlet obstruction, adjacent colon resection, advanced TNM stage 
(III and IV), preoperative CRP level ≥ 1.35 mg/L, POD3 CRP 
level ≥ 107.15 mg/L, POD3 NLR ≥ 5.51, and POD3 PLR 
≥ 167.47 had significant association with PPOI (Supplementary 
Table 3). In the multivariate analysis, age ≥ 60 years (OR, 1.728; 
95% CI, 1.020-2.927; P = 0.024), adjacent colon resection (OR, 
6.073; 95% CI, 1.145-32.225; P = 0.034), POD3 CRP level 
≥ 107.15mg/L (OR, 2.258; 95% CI, 1.344-3.794; P = 0.002), 
POD3 NLR ≥ 5.51 (OR, 1.861; 95% CI, 1.112-3.114; P = 
0.018) were independent risk factors for PPOI in patients who un-
derwent laparoscopic surgery.
Discussion 
This study showed that peri-operative inflammatory mark-
ers had independent association with the development of PPOI. 
Several previous studies reported that there is a correlation between 
systemic inflammation and complication after cancer surgery.15 
However, this study is the first to report the relationship between 
the incidence of post-operative PPOI and inflammatory markers in 
gastric cancer surgery.
CRP level, NLR, and PLR are simple, readily measurable 
laboratory markers. However, the optimal cutoff values for CRP 
level, NLR, and PLR to predict PPOI remains unclear. Varying 
normal levels of CRP are defined by institutes (< 6 mg/L in our 
center), but there is no determined cutoff value for NLR and PLR. 
A cutoff value of 5 for NLR is often chosen on the basis of previous 
studies and used in clinical practice although different values have 
been used in studies on colorectal cancer.17 In another study, the 
cutoff value of NLR was 2.5 for bladder cancer,18 and 4.0,13 2.57,19 
and 1.4420 for gastric cancer. The cutoff value or PLR is 16019 and 
18020 for gastric cancer. In our study, we identified the optimal cut-
off for CRP level, NLR, and PLR using ROC curve analysis.
An elevation in CRP level is considered to be associated with 
the immune system and poor survival.21 Further, the elevation in 
NLR and PLR has recently been identified as a strong prognostic 
marker for multiple malignancies, including colorectal cancer,22 
pancreatic ductal adenocarcinoma,23 and others.12,24-27
The relationship between elevated inflammatory markers and 
infectious complications after operation remains unclear; how-
ever, NLR may provide a possible explanation. An increase in the 
number of neutrophils is induced by bacterial contamination of the 
operation site.28 A high NLR reflects both strengthened neutrophil-
induced inflammatory response and weakened lymphocyte-mediat-
ed antibacterial response, which has been believed to affect various 
cancer patients, including those with gastric cancer.29-31 Stimulated 
immature neutrophils which tend to release superoxide anions in 
response to surgical stress, may influence oxygen radical-mediated 
tissue injury and bacterial invasion of the surgical site.31 
Although the precise mechanism remains unclear, the results of 
this study suggest that NLR as a simple inflammatory biomarker, 
may identify patients at increased risk for post-operative complica-
tions after gastrectomy for gastric cancer. Many studies have been 
conducted to identify whether NLR is superior to PLR. According 
to these studies, neutrophilia in contrast to thrombocytosis is a more 
sensitive reaction and could represent the inflammatory activity of 
the tumor.27,28 Cancer-related inflammation, characterized by an 
elevation of NLR, induces decrease of antitumor immunity via the 
accumulation of regulatory T cells and elevated secretion of chemo-
kines resulting in tumor growth and metastasis. Therefore, inflam-
mation may result in aggressive growth of the tumor. Alternatively 
host cell immunity could be deteriorated by the cancer, thereby af-
fecting the host’s outcomes such as post-operative complications.28
Various factors involved in POI act by reducing the contractil-
ity of the muscularis externa (ME) and delaying the GI transit 
time. These typical factors include anesthetics, post-operative drugs, 
and inflammatory mediators secreted by immune cells.32,33 In nor-
mal conditions, ME macrophages respond to luminal bacterial 
infection and interact with enteric neurons to regulate GI motility.34 
When macrophages are stimulated by luminal bacterial infections, 
leukocytes, especially monocytes and neutrophils, are attracted to 
the ME. When surgical stimulus is added, ME macrophages are 
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activated, leading to a decrease in muscle contraction and a delay 
in intestinal transit.35 In rodents, inactivation of macrophage before 
surgery inhibited the activity of leukocytes and improved GI tran-
sit.36 In addition, anti-inflammatory mediators such as interleukin 
(IL)-10 and polyunsaturated fatty acids-derived pro-resolving mol-
ecules are involved in the recovery of intestinal motility.37-40 Based 
on previous studies that confirm their relation to inflammation and 
POI, peri-operative inflammatory markers can be used as a tool for 
predicting PPOI. 
Among peri-operative inflammatory markers, preoperative 
NLR and POD1 NLR were independent risk factors for PPOI 
in open surgery. In the case of laparoscopic surgery, POD3 CRP 
levels and POD3 NLR were independent risk factors for PPOI. 
This result may be associated with difference of surgical range be-
tween open and laparoscopic gastrectomy. Since surgical range and 
stress of open surgery is more extensive and stronger than laparo-
scopic surgery, neutrophil-induced inflammatory response may be 
activated earlier in the patients after open surgery than laparoscopic 
surgery.
Our study has several limitations. First, this study is limited by 
its retrospective design. Second, the use of medication for pain con-
trol was not considered, especially exogenous opioids, which may 
contribute to impaired GI motility and affect POI. Third, patients 
who underwent previous treatments, such as endoscopic mucosal 
resection or endoscopic submucosal dissection, were included. 
These interventions can alter preoperative inflammatory markers.
In conclusion, although preoperative tumor staging is valuable 
for selecting the appropriate therapeutic strategy for patients with 
gastric cancer, clinical tumor staging alone cannot predict post-
operative complication and prognosis.41 Our study suggests that 
the peri-operative systemic inflammatory markers, which is easily 
measurable, may be clinically useful to identify patients at increased 
risk for PPOI and predict longer post-operative hospitalization. 
The inflammatory markers should be routinely monitored in 
order to identify an abnormal response, complications, and infection 
in advance.
The administration of therapeutic agents such as prokinetics 
or prophylactic antibiotics, should be considered targeting the var-
ied aspects of the systemic inflammatory response. Further study 
on medications for the modulation of systemic inflammation to 
improve peri-operative outcomes after resection for cancer will be 
needed.
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